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NEUROLOGICAL MANIFESTATIONS OF COVID-19: PATHOGENESIS, 






The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), continues to cause substantial morbidity and mortality 
worldwide. The first part of this thesis will review the background of SARS-CoV-2 and 
the potential mechanisms of neuroinvasion. The cytokine storm is implicated in the 
pathogenesis of many of the neurological conditions discussed in this paper. The 
molecular and histological evidence further support the possible association of SARS-
CoV-2 with these conditions. Next, the diagnosis and therapeutic interventions of 
neurological conditions of SARS-CoV-2 will be investigated. The neurological 
manifestations associated with COVID-19 will be divided into two categories, acute and 
long-term sequelae. The acute COVID-19 associated neurological conditions reviewed 
include Guillain-Barré syndrome, seizures, strokes, anosmia, multisystem inflammatory 
syndrome in children (MIS-C), and multisystem inflammatory syndrome in adults (MIS-
A). The long-term neurological sequelae of COVID-19 discussed include a psychiatric 
disorder, depression and a neurodegenerative disorder, Alzheimer’s disease (AD). The 
review of the current literature suggests that COVID-19 could be associated with acute 
neurological diseases. However, the long-term sequelae of COVID-19 needs further 
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investigation since this is a novel virus and there is limited evidence currently. However, 
the evidence continues to grow as more clinicians and researchers recognize the 
extrapulmonary manifestations of COVID-19. An awareness of the neurological impact 
this disease can have is critical for patient management and the appropriate public health 
response. Having a better understanding of the neurological impact of this disease will 
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in 
Wuhan, China in December 2019 from a cluster of severe pneumonia cases (Zhu et al., 
2020). Subsequently, the disease caused by SARS-CoV-2 was named as Coronavirus 
Disease 2019 (COVID-19) and on March 11, 2020 the World Health Organization 
(WHO) declared the COVID-19 pandemic. As of March 17th, 2021, SARS-CoV-2 has 
infected more than 120 million people and caused more than 2.5 million deaths globally 
(WHO, n.d.). The common clinical presentations of COVID-19 include fever and 
respiratory symptoms such as dry cough and shortness of breath (Jiang et al., 2020). The 
lower and upper respiratory tracts are the main sites affected by SARS-CoV-2 infection. 
It presents as mild respiratory symptoms to more severe pneumonia and the acute 
respiratory distress syndrome (ARDS) (Wang, Kream, & Stefano, 2020; Cevik, Bamford, 
& Ho, 2020; Barth, Buja, & Parwani, 2020). The main system affected by SARS-CoV-2 
is the respiratory system; however, there is continuing evidence that extrapulmonary 
systems can be affected as well (Gupta et al., 2020; Mao et al., 2020; Dufort et al., 2020). 
The mechanism of SARS-CoV-2 causing neurological symptoms needs to be explored. 
Pro-inflammatory cytokines have been demonstrated to cause tissue damage in lungs, and 
if these cytokines affect the CNS, they may cause neurological symptoms in patients. 
(Leonardi, Padovani, & McArthur, 2020). The main objective of this work is to perform a 
comprehensive review of acute and chronic neurological manifestations associated with 
SARS-CoV-2 infection and provide insights into the potential mechanisms of 
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neuroinvasion and pathogenesis. The acute neurological conditions that will be reviewed 
include anosmia, seizures, strokes, and Guillain- Barré syndrome. In addition, 
neurological manifestations associated with the emerging, multisystem inflammatory 
syndrome in children (MIS-C) and multisystem inflammatory syndrome in adults (MIS-
A) will also be assessed. Long-term neurological sequelae – associated with COVID-19 
patients including a psychiatric disorder, depression and a neurodegenerative disease, 
Alzheimer’s disease will also be reviewed.  
 
The first part of this thesis will review the background of SARS-CoV-2, the mechanisms 
of neuroinvasion, and molecular and histological evidence of the coronavirus in the brain. 
Next, the current studies about neurological conditions associated with COVID-19 will 
be presented. The pathogenesis, diagnosis and therapeutic interventions of the 












Background of SARS-CoV-2 
Coronaviruses belong to the order Nidovirales, family Coronaviridae and subfamily 
Coronavirinae (Richman, Whitley, & Hayden, 2016). The subfamily Coronavirinae is 
further subdivided into either Alphacoronavirus, Betacoronavirus, Gammacoronavirus, 
or Deltacoronavirus based on their phylogenetic clustering (Huang et al., 2013; Fehr & 
Perlman, 2015). These positive-sense RNA viruses infect a wide range of mammals 
including humans (Richman et al., 2016). Figure 1 below shows severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) is composed of four structural proteins, spike 
protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N) 
(Zakeri, Jadhav, Sullenger, & Nimjee, 2021; Chen et al., 2020). The components of the 
virus called the spike protein make up the signature crown-like shape. The spike 
glycoproteins are particularly immunogenic, which leads to an immune response (Chen et 
al., 2020; Richman et al., 2016; Soy et al., 2020). Since SARS-CoV-2 is a novel virus, 
previous human Betacoronaviruses, such as severe acute respiratory syndrome 
coronavirus (SARS-CoV) and Middle East respiratory coronavirus syndrome (MERS-
CoV) can be useful for predicting systems affected since they all share highly 
homologous sequences and infection pathways (Huang et al., 2013; Li, Bai, & 
Hashikawa, 2020; Asadi-Pooya, 2020). The similarity in clinical presentations of MERS-
CoV, SARS-CoV, and SARS-CoV-2 infections indicates similar pathogenesis as well 




Figure 1. Structural elements of SARS-CoV-2. Taken from (Zakeri et al., 2021). 
 
Neuroinvasion by Coronaviruses 
Emerging studies suggest that even though COVID-19 primarily affects lungs and 
airways, it also impacts other organs, particularly in severe cases (Varga et al., 2020; 
Gupta et al., 2020). SARS-CoV-2 employs angiotensin-converting enzyme 2 (ACE2) as a 
receptor for cellular entry. ACE2 has been detected mainly in respiratory tissues (Gupta 
et al., 2020; Barth et al., 2020). ACE2 expression in extrapulmonary tissues such as glial 
cells and neurons has been reported  and may indicate the potential of extrapulmonary 
infection of SARS-CoV-2 (Kanwar, Baig, & Wasay, 2020). There is evidence that human 
coronaviruses (HCoV) are neuroinvasive (Arbour, Day, Newcombe, & Talbot, 2000). For 
instance, the HCoV strain 229E can infect endothelial cells in brain tissue (Arbour et al., 
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2000). Blood vessels are lined by endothelial cells. The ability of other HCoV strains to 
infect endothelial cells provides a rational to explore if SARS-CoV-2 can as well. 
Coronaviruses have the ability to spread from the respiratory tract to the central nervous 
system (CNS) leading to neurotropism (Desforges, Le Coupanec, Stodola, Meessen-
Pinard, & Talbot, 2014). The SARS-CoV-2 neurotropism (i.e., the ability to invade 
neural tissue) may be implicated with the central nervous system including the olfactory 
nerve, thalamus and brainstem (Li, Yan-Chao et al., 2020). Once the virus has made its 
way to the central nervous system, the cerebral spinal fluid (CSF) and brain tissue may be 
invaded in less than a week (Asadi-Pooya, 2020). Figure 2 below shows how SARS-
CoV-2 entering the CNS through the olfactory nerve.  
Studies involving mice transgenic for human ACE2 have shown that SARS-CoV 
can enter the brain though the olfactory bulb (Netland, Meyerholz, Moore, Cassell, & 
Perlman, 2008; Li, K. et al., 2016).  
Additionally, ACE2 is upregulated in nasal goblet and ciliated cells of nasal 
passages; thus, the neuroinvasion of SARS-CoV-2 via the olfactory bulb and nerve seem 
more plausible (Abate, Memo, & Uberti, 2020). Other routes of entry such as the 
hematogenous route, synapse-connected route, lymphatic system, and nerve terminals 
could also allow SARS-CoV to invade the CNS and lead to neuropathology (Xu et al., 





Figure 2. The Mechanism of SARS-CoV-2 Entry into the CNS. Demonstrates how SARS-CoV-2 infection can 
indirectly and directly cause neurological conditions due to a cytokine storm and through the infection of the 
olfactory nerve, respectively. CNS, central nervous system. BBB, blood-brain-barrier. Figure taken from (Orsini 
et al., 2020). 
 
 
Cytokine Storm  
Patients infected with SARS-CoV have been found to have increased levels of 
proinflammatory cytokines such as interleukins, including IL-1 and IL-6, and 
chemokines, including IL-8 (Richman et al., 2016). An acute increase in pro-
inflammatory cytokines can be triggered by a viral infection such as one by SARS-CoV-2 
(Ragab, Eldin, Taeimah, Khattab, & Salem, 2020). SARS-CoV-2 has a stronger affinity 
to the ACE2 receptor when compared to SARS-CoV (Kempuraj et al., 2020). Stronger 
binding to the ACE2 receptor may contribute to an exaggerated immune reaction in 
response to a SARS-CoV-2 infection (Kempuraj et al., 2020). Also, interleukin-6 (IL-6) 
is the cytokine that can upregulate the immune response and is most frequently associated 
with COVID-19 patients (Ragab et al., 2020; Kempuraj et al., 2020). The exaggerated 
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and sudden inflammatory response is referred to as the ‘cytokine storm’ (Wang et al., 
2020). The antiviral immune response stimulates immune and endothelial cells to 
produce cytokines, the key ones being interleukin-1 (IL-1), tumor necrosis factor-alpha 
(TNF-a), and interferon (Ragab et al., 2020). Also, there is a positive association 
between IL-6 levels in the serum and mortality (Ragab et al., 2020). Macrophages, T 
cells, and other immune cells are recruited to the infection site and reduce the integrity of 
endothelial layers (Ragab et al., 2020). As a result, a cytokine storm destabilizes vascular 
barriers and increase their permeability in the CNS (Teuwen, Geldhof, Pasut & 
Carmeliet, 2020). The expression of the SARS-CoV-2 spike (S) protein binding receptor, 
ACE2, within the brain vasculature and/or the effects of the cytokine storm may 
compromise the blood-brain barrier (Leonardi et al., 2020; Wang et al., 2020). 
Furthermore, breaches in the endothelial cell and basement membrane layer are 
associated with inflammatory mediators as shown in Figure 3 (Kempuraj et al., 2020).  
There is evidence that the cytokine storm is implicated with the coagulation 
pathways in various organs including the brain (Fotuhi, Mian, Meysami, & Raji, 2020; 
Teuwen et al., 2020). The damaged vasculature exposes the basement membrane which 
leads to events that activate platelet production and other factors that promote clotting 




Figure 3. Pro-inflammatory cytokines in brain parenchyma. Taken from (Kempuraj et al., 2020). 
 
It is probable that pro-inflammatory cytokines are implicated with both acute and chronic 
neurological conditions. For future studies, the degree to which neurological disorders are 












Molecular and Histological Evidence of SARS-CoV-2 in the Brain  
Bhatnagar et al. used molecular techniques to evaluate autopsy tissues from patients with 
confirmed COVID-19 (Bhatnagar et al., 2021). In this autopsy case series, reverse-
transcription polymerase chain reaction (RT-PCR) was used to identify which tissue 
samples were infected with the virus. In situ hybridization (ISH) was performed on 
various tissues positive by RT-PCR; ISH allows SARS-CoV-2 RNA to be localized in 
tissue and thus visualized. Panel A1 and A2 of Figure 4 show ISH staining, 
demonstrating SARS-CoV-2 RNA in the vascular endothelial cells and vessel wall of the 
blood vessels in the cerebellar leptomeninges and brain stem of a fatal COVID-19 case. 
Notably, the patient had co-morbidities (cardiovascular disease and diabetes) that are 
characterized by pre-existing vascular dysfunction with altered endothelial cell 
metabolism (Bhatnagar et al., 2021). Arbour et al. reported that two strains of HCoV, 
OC43 and 229E were detected in brain tissue by reverse-transcription polymerase chain 
reaction (RT-PCR) and Southern hybridization; this data supports the presence of 
respiratory pathogens in the CNS (Arbour et al., 2000). Direct viral infection can cause a 
disturbance by triggering an immune response and increasing pro-inflammatory 
cytokines (Arbour et al., 2000; Bhatnagar et al., 2021; Wang et al., 2020). However, 
further investigation into the virus-induced injury and associated host inflammatory 




Figure 4. In-situ Hybridization (ISH) Staining in Multiple Tissue Types. Panel A1 and A2 show staining in brain 
tissue, the cerebellar leptomeninges and brain stem, respectively. Taken from (Bhatnagar et al., 2021). 
 
Another case report demonstrated that a patient with confirmed SARS-CoV presented 
with typical coronavirus symptoms such as fever, chills, and malaise, but also presented 
with headache, dizziness and myalgia (Xu et al., 2005). Histopathologic examination of 
brain tissue from this patient infected with SARS-CoV showed necrosis and other 
neuropathology suggesting neuroinvasion by SARS -CoV (Xu et al., 2005).   
This case report gives insight into the pathology and neurological manifestations SARS-










Clinical Features of COVID-19  
The clinical presentations of COVID-19 have a wide range of symptoms as shown in 
Table 1 below (Mao et al., 2020). The most well-known presentations of COVID-19 
include fever and respiratory symptoms such as cough and shortness of breath (Jiang et 
al., 2020). COVID-19 is known to have a profound effect on respiratory pathology, but 
neurological pathologies seem to be heavily affected as well. Mao et al. found that out of 
214 patients with COVID-19, 36.4% of those patients presented with neurologic 
symptoms (Mao et al., 2020). Neurologic symptoms presented by the patients in their 
study included dizziness, headache, and smell impairment. They also reported 4 of the 
214 patients had an ischemic stroke, and one, a cerebral hemorrhage. 
Neurological manifestations of COVID-19 need to be explored since the 
prognosis of patients remain unclear.  Other studies have shown that patients with 
COVID-19 present with neurological symptoms such as headache, dizziness, impaired 
consciousness, loss of taste, and loss of smell (Huang et al., 2020; Mao et al., 2020, Chen 
et al., 2020). According to Table 1, the severity of the SARS-CoV-2 infection is 
correlated to the presentation of neurological symptoms. (Mao et al., 2020). It is not a 
surprise that the mean age of severe patients (58.2) is higher than nonsevere patients 
(48.9), as older adults may be more likely to have some underlying health conditions 
(Mao et al., 2020). Especially during the pandemic, it is imperative for clinicians to 
suspect SARS-CoV-2 infection when a patient presents with neurological symptoms; 
symptoms present early in infection and the patients may not have developed typical 
symptoms such as fever and cough (Mao et al., 2020).  
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The data from the Mao et al. study may be misleading due to the source being electronic 
medical records from hospitalized COVID-19 patients (Mao et al., 2020). The use of 
diagnostic tools such as magnetic resonance imaging (MRI) and electromyography were 
infrequent due to the precautions during the pandemic (Mao et al., 2020). Most of the 
recorded neurological symptoms could not be quantitated, so the data from their study is 
subjective. If neurological manifestations are more prevalent in patients with cognitive 
impairments, the methods of collecting data are reduced in this population. It remains a 
challenge whether COVID-19 patients who present with neurological symptoms had 





Table 1. Clinical Symptoms of COVID-19 Patients. The symptoms presented by patients with severe and 
nonsevere disease are shown. A P value less than .05 indicates a statistical significance between the two patient 
groups, severe and nonsevere. CNS, central nervous system; PNS, peripheral nervous system; SD, standard 





According to the Mao et al. study, it is beneficial to have patients presenting with 
neurologic symptoms to be screened for SARS-CoV-2 infection both for clinical and 
epidemiological reasons (Mao et al., 2020). The clinical presentation of COVID-19 varies 
widely, and thus it is possible to have a SARS-CoV-2 infected patient present only with 
neurological symptoms (Fotuhi et al., 2020). Increased neurological symptoms and 
decreased flu-like symptoms may be seen in elderly patients and patients with 
comorbidities (Orsini et al., 2020). When COVID-19 presents as a non-infectious 
neurological condition, it is crucial for neurologists to suspect the possibility it is 
COVID-19 and to isolate the patient. Timely management of neurological manifestations 












PUBLISHED STUDIES  
 
This section of the paper will review acute and long-term sequelae of neurological 
conditions associated with COVID-19. In the short time period since the Mao et al. study 
was published, more studies have continued to be published demonstrating the high 
occurrence of neurological symptoms among COVID-19 patients. Recent published 
studies that showcase the neurological manifestations of COVID-19 will be reviewed.  
 
Acute Neurological Manifestations of COVID-19 
 
The acute neurological manifestations of COVID-19 will be discussed. The acute 
manifestations that will be reviewed are Guillain- Barré syndrome, seizures, strokes, 
anosmia, MIS-C, and MIS-A. Due to the short duration of the following neurological 
conditions, the association with COVID-19 are well-defined.  
 
Guillain-Barré Syndrome 
Guillain-Barré syndrome (GBS) is a rare autoimmune disorder that causes peripheral 
paralysis (Dalakas, 2020). It is an acute syndrome since it takes 1-4 weeks to develop the 
maximum severity of ascending motor weakness, sensory abnormalities, and other related 
nerve dysfunction (Dalakas, 2020; van den Berg et al., 2014). GBS consists of subtypes; 
the subtypes are based on how the clinical symptoms present due to the area of nervous 
system involvement (Dalakas, 2020). Subtypes of GBS include acute inflammatory 
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demyelinating polyradiculoneuropathy (AIDP) and Miller Fisher syndrome (MFS) 
(Dalakas, 2020). GBS is known to have a viral etiology; 70% of patients developed the 
syndrome after experiencing some type of viral illness such as hepatitis, influenza, and 
Epstein-Barr virus (Dalakas, 2020).  
The first case of GBS associated with COVID-19 was reported in a 61-year-old 
female patient who presented with acute lower limb weakness and fatigue (Zhao, Shen, 
Zhou, Liu & Chen, 2020). Interestingly, the patient did not show any indication of having 
COVID-19 due to absence of fever and respiratory symptoms. Laboratory findings 
revealed lymphocytopenia (low lymphocyte count) and thrombocytopenia (low platelet 
count). Her clinical presentation and nerve conduction study results indicated she had 
demyelinating neuropathy, leading to a diagnosis of GBS. Eight days after hospital 
admission, she showed typical symptoms of COVID-19 and tested positive for SARS-
CoV-2. Thrombocytopenia and lymphocytopenia, common in COVID-19 patients, 
indicate she was already infected with SARS-CoV-2 before the onset of her symptoms. 
The simultaneous presentation of GBS and SARS-CoV-2 infection support the cause of 
GBS was the infection. In another study by Caress et al., only 2 out of 37 patients 
presented with GBS symptoms before they showed an indication of a SARS-CoV-2 
infection (Caress et al., 2020). The researchers also reported that the rest of the patients 
showed signs of GBS after the onset of COVID-19 symptoms. The findings from these 
studies support SARS-CoV-2 associated GBS occurs, even when the patient is 
asymptomatic for COVID-19 (Caress et al, 2020; Zhao et al., 2020). In addition, the 
severity of GBS is linked to the type of pathogen involved, but it seems the COVID-19 
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associated GBS cases present themselves similarly to cases not linked to COVID-19 (van 
den Berg et al., 2014; Caress et al., 2020). 
The pathogenesis of Guillain-Barré syndrome involves the attack of healthy cells 
after some sort of infectious agent, bacterial or viral (van den Berg et al., 2014). The 
studies above suggest SARS-CoV-2 can one of the pathogens to initiate the autoimmune 
response (van den Berg et al., 2014). Antigens of infectious pathogens such as SARS-
CoV-2 have sequence similarities to self-peptides leading to T and B cells attacking the 
body’s own cells and tissues (van den Berg et al., 2014). In GBS patients, the antibody 
immune response attacks gangliosides, molecules that are predominantly found in the 
nervous system (van den Berg et al., 2014). In addition, the complement system is 
involved in the destruction of nerves, most likely at the nodes of Ranvier (van den Berg 
et al., 2014). High creatine kinase levels in patients reflect the dysfunction related to the 
muscles and nervous system (Dalakas, 2020).  
 
Diagnosis and Treatment of GBS 
 
The prominent features of GBS such a symmetrical weakness of limbs and sensory 
deficits, make it possible to diagnose this syndrome with a neurological exam (van den 
Berg et al., 2014). In addition, lumbar puncture procedures can be done in conjunction; 
increased protein levels indicate GBS, and it is a reliable measure as approximately 80% 
of patients have elevated levels after one week of GBS symptoms (van den Berg et al., 
2014). Nerve conduction studies are also used to identify the subtype of GBS. However, 
the dysfunction of nerve conduction is usually observed until more than two weeks after 
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the first symptoms of GBS (van den Berg et al., 2014). Intravenous immunoglobulin 
(IVIG) is a common and effective treatment method; (van den Berg et al., 2014; Caress et 
al., 2020). IVIG is beneficial for patients with immune deficiencies since this therapy 
transfers healthy polyclonal IgG into their system (Soy et al., 2020). However, healthcare 
providers should be aware that IVIG is known to be implicated with coagulopathy (Soy et 
al., 2020; Caress et al., 2020).   
 
Seizures 
Researchers in Iran found that the mortality rate of COVID-19 patients in their study was 
approximately 1.8%. However, they also reported that their patients presenting with 
seizures had an 80% mortality rate (Emami et al., 2020). This significant finding gives 
reason to further investigate the etiology of the COVID-19 associated seizures.   
There are previous case studies that indicate coronaviruses may cause seizures 
(Lau et al., 2004; Hung et al., 2003). During the SARS outbreak in 2002-2004. Lau et al. 
gave a case report of a 32-year-old female patient who was previously healthy and 
presented with an unproductive cough (dry cough), fever, chills, and diarrhea (Lau et al., 
2004). Her health deteriorated quickly; she had convulsions and loss of consciousness 22 
days after symptom onset. A SARS-CoV RT-PCR test showed that her cerebrospinal 
fluid (CSF) was positive, indicating that the virus entered her CNS. In a similar study by 
Hung et al., a 59-year-old female patient presented with a productive cough, fever, chills, 
and diarrhea (Hung et al., 2003). Within five days of hospital admission the patient 
experienced confusion, developed respiratory failure, and began seizing. Computer 
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tomography (CT) scans showed no abnormalities, but a real-time RT-PCR test showed 
her CSF was positive for SARS-CoV. Both case studies demonstrate CSF infection by 
SARS-CoV shortly followed by seizures (Lau et al., 2004, Hung et al., 2003). A more 
recent study by Vollono et al. gave a case report of a 78-year-old female patient who 
presented with myoclonic jerks and focal status epilepticus (prolonged or recurrent 
epileptic activity) and had a history of hypertension and post-encephalitic epilepsy 
(Vollono et al., 2020; Dulac & Takahashi, 2013). However, the patient’s non-convulsive 
status epilepticus was controlled with antiepileptic drugs and neurologic follow-ups; 
therefore, she had not had any seizures for more than two years. Nasopharyngeal swabs 
tested positive by SARS-CoV-2 real time RT-PCR. Although the patient had a history of 
seizures prior to SARS-CoV-2 infection, the condition was well-managed. The sudden 
development of seizures after the infection supports the association between COVID-19 
and seizures. It is also important to discuss recent COVID-19 case reports that involve 
non-epileptic patients. Hepburn et al. report cases on two older adult male patients 
confirmed to have COVID-19 with a history of lung disease (Hepburn et al., 2021). A 
few days after hospital admission, they presented with acute encephalopathy and 
seizures. Both patients developed focal seizures and one patient developed non-
convulsive status epilepticus.  
The various case presentations described above, could be beneficial for detecting 
future case patients with COVID-19 who may develop seizures. A limitation in the recent 
SARS-CoV-2 case studies described is that SARS-CoV-2 PCR testing in the CSF was 
not available. CSF testing is unlikely to become a routine diagnostic tool for COVID-19 
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due to the expense and invasiveness. The past SARS-CoV cases help determine if there is 
a cause and effect relationship between COVID-19 and seizures. 
The pathogenesis of seizures is most likely implicated with the cytokine storm. 
SARS-CoV-2 enters the CSF and creates a hypercoagulable state that makes it an ideal 
environment for the virus to interact with ACE2 receptors on neural cells (Hepburn et al., 
2021). Elevated levels of pro-inflammatory cytokines leads to cortical irritation that 
predisposes the patient to have seizures (Hepburn et al., 2021). Therefore, an overreactive 
inflammatory response that makes way for cytokine and SARS-CoV-2 entry into the 
blood-brain barrier causes seizures (Fotuhi et al., 2020; Hepburn et al., 2021).  
 
Diagnosis and Treatment of Seizures 
 
Seizures can be diagnosed using patient health assessments/histories and diagnostic 
imaging (Gavvala & Schuele, 2016). A common imaging test used for diagnosing 
seizures is electroencephalography (EEG). EEGs can detect abnormal electrical signals in 
the brain (Gavvala & Schuele, 2016; Vollono et al., 2020).  
COVID-19 patients without previous history of seizures should not take long-term 
anti-seizure medication (Emami et al, 2020). It is important to note that seizures can have 
a non-viral cause such as hypoxia, metabolic dysfunction, or some form of brain injury 
(Asadi-Pooya, 2020). When a COVID-19 patient is seizing, it may be manageable if it is 
known that non-viral cause is the source of the seizure (Asadi-Pooya, 2020). 
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Since there are occurrences of COVID-19 patients having seizures, it is critical for 
healthcare providers to be aware of the drug-drug interactions for COVID-19 medications 
and anti-seizure medication (Asadi-Pooya, 2020).  
There is evidence that the COVID-19 pandemic is straining the medical care of 
patients with chronic health conditions. A study in Germany was interested to see if the 
coronavirus pandemic affected outpatient epilepsy care because hospital capacity for 
routine care were limited due to the preparation for COVID-19 patients (Mueller et al., 
2021). The study found that anti-seizure medication prescribed for new epilepsy patients 
decreased during the course of the pandemic (April 2020 to May 2020). The decrease in 
prescriptions supports the researchers’ hypothesis that outpatient epilepsy care and most 
likely other chronic conditions were negatively impacted. However, the researchers found 
that the number of anti-seizure medications prescribed for established epilepsy patients 
increased prior to March 2020. In another study, a similar pattern was seen for 
medications for diabetes and cardiovascular conditions (Kostev, Kumar, Konrad, & 
Bohlken, 2020). For established patients with known chronic conditions, the increased 
prescriptions may be due to patients preparing for the lockdown. For new patients, it is 
likely that the limited capacity in healthcare settings is one of many factors contributing 
to the underdiagnoses. Other factors that strained outpatient care such as the fear of 
becoming infected with SARS-CoV-2 and the inability to travel to hospitals need to be 





The occurrence of stroke in COVID-19 patients is concerning, especially in the younger 
population since their incidence of stroke is normally low (Zakeri et al., 2021). The rise 
in stroke incidence in younger, previously healthy COVID-19 patients indicates that this 
disease is related to COVID-19. There are several published studies that show an 
association between COVID-19 and strokes. Mao et al. reported 5 of 214 patients in their 
study either had an ischemic stroke (4) or cerebral hemorrhage (1). In another study, Li, 
Yanan et al. conducted a retrospective observational study on 219 COVID-19 patients 
and found that 11 (5.0%) presented with either ischemic stroke (10) or had an 
intracerebral hemorrhage (1) (Li, Yanan et al., 2020). According to Table 2, of the 11 
patients who developed acute cerebrovascular disease, 9 (81.8%) had severe COVID-19 
infection (Li, Yanan. et al,. 2020). This study supports the hypothesis that the presence of 
neurological symptoms indicates a more severe case of COVID-19 or an advanced 
progression of the disease (Leonardi et al., 2020). The study by Mao and colleagues 
supports this hypothesis (Mao et al., 2020). The researchers found that  severity of the 
SARS-CoV-2 infection is correlated to the presentation of neurological symptoms. (Mao 
et al., 2020). 
 
COVID-19 is associated with thrombosis, or the formation of a blood clot in the 
arteries and veins (Zakeri et al., 2021). The thrombosis most likely is formed when a viral 
pathogen such as SARS-CoV-2 triggers the innate immune system and a cytokine storm 
forms (Zakeri et al., 2021). The cytokine storm creates a hyper-inflammatory 
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environment including increased levels of IL-6, which is implicated in the coagulation 
pathway (Zakeri et al., 2021). The pro-inflammatory cytokines promote expression of 
tissue factor (TF) on the surrounding endothelial cells. TF goes through a series of events 
that lead to the activation of thrombin and platelets (Zakeri et al., 2021).  
 





There is increasing evidence that a SARS-CoV-2 infection causes acute 
inflammation; the proinflammatory cytokines and other inflammatory factors are 
implicated with formation of blood clots in the brain (Fotuhi et al., 2020). In addition, the 
renin angiotensin system (RAS) may be involved with strokes in COVID-19 patients 
(Hess, Eldahshan, & Rutkowski, 2020). Hess et al. theorize that when SARS-CoV-2 
binds to ACE2, the virus depletes ACE2 and increase levels of ACE1 and angiotensin II 
(Hess et al., 2020). Angiotensin II promotes vasoconstriction and inflammation, two 
factors implicated with stroke.  
 
Diagnosis and Treatment of Stroke 
 
There are many tests that can be used to diagnose a stroke. Inflammation is implicated 
with strokes, thus tests measuring C-reactive protein (CRP) can be used to indicate stroke 
(Hess et al., 2020). Blood clots are fibrin-rich, and the breakdown of fibrin creates protein 
fragments called D-dimers (Teuwen et al., 2020). Thus, increased levels of D-dimers 
indicate blood clot presence in a patient (Teuwen et al., 2020; Barth et al., 2020). 
Measuring D-dimer levels, IL-6, and C-reactive creatinine is extremely useful because 
these markers assess a patient’s risk of developing a blood clot and indicates the severity 
of their disease (Majidi et al., 2020; Zakeri et al., 2021). A CT scan can be used to 
confirm a stoke diagnosis (Figure 5) (Hess et al., 2020). Anticoagulants should be used 
with caution because they are a risk factor for hemorrhage. Anticoagulants inhibit 
thrombin production by interfering with clotting factors (Zakeri et al., 2021). 
Antiplatelets help reduce the platelet aggregation triggered by inhibiting thromboxane, 
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the enzyme that facilitates this aggregation. Antiplatelets inhibit neutrophil activation 
(Zakeri et al., 2021). 
 
 
Figure 5. A CT Demonstrating Acute Infarct. The left occipital and parietal lobes are the areas affected. Taken 
from (Avula et al., 2020). 
 
Strokes can be treated with tPA and anticoagulants such as heparin (Hess et al., 2020). 
Patients with increased D-dimer levels had a better clinical outcome when treated with 
heparin (Hess et al., 2020). Another treatment tailored for COVID-19 patients undergoing 





The Chemosensory System: Anosmia and Ageusia   
Normal olfactory function is called normosmia; olfactory dysfunction can be categorized 
into hyposmia, in which the loss of smell is partial, and functional anosmia, in which 
there is complete loss of smell (Whitcroft and Hummel, 2019). The sudden loss of smell, 
anosmia, and taste, ageusia, seem to be prevalent among COVID-19 patients. The 
chemosensory system is functional with the activation of olfactory receptor neurons, 
which occurs when airborne molecules passes through the olfactory cleft (Whitcroft & 
Hummel, 2019). These olfactory receptor neurons are embedded in the neuroepithelium 
of the olfactory cleft. The perception of smell may also need the activation of the 
trigeminal nerve in order to function (Whitcroft & Hummel, 2019). Post infectious 
olfactory dysfunction involving the olfactory neuroepithelium, the olfactory nerve, or 
other areas of the olfactory system may occur after upper respiratory tract infection 
(Figure 6) (Whitcroft & Hummel, 2019; Izquierdo-Dominguez, Rojas-Lechuga, Mullol, 
& Alobid, 2020). It has been shown that the Alphacoronavirus (HCoV-229E) affects the 
ciliary nasal epithelium (Chilvers et al., 2001). The phenomenon of losing smell, 
anosmia, may be associated with neurotropism since epithelial cells express angiotensin-
converting enzyme 2 (ACE2) (Brann et al., 2020; Barth et al., 2020). 
 
In a study looking at an outpatient population at a coronavirus testing center, 22 of 34 
(64.7%) COVID-19 positive patients were assessed to have sudden loss of smell and taste 
(Haehner, Draf, Dräger, de With, & Hummel, 2020). The researchers noted the loss of 
smell and taste was most likely independent of nasal obstruction since a severe 
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congestion was not common among patients (Haehner et al., 2020). Sudden loss of smell 
is one COVID-19 symptom that can be utilized to contribute significantly to aid in 
contact tracing and prevention of the outbreak. Thus, anyone experiencing this particular 
symptom during the pandemic should self-isolate and undergo testing for SARS-CoV-2.  
 
Figure 6. Mechanism of Neurodegenerative Effects of SARS-CoV-2 Infection in the Olfactory System. OB = 








Diagnosis and Treatment of Anosmia 
 
Anosmia is important to include in the diagnostic criteria for COVID-19 since 
approximately 12% of patients have anosmia before showing any other symptoms.  
According to the Table 3, the percentage of COVID-19 patients experiencing loss in taste 
and smell had a large range. The wide range of anosmia prevalence shown in Table 3 
may be due to inconsistencies in assessing for anosmia.  
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Table 3. Summary of Published Data on Olfactory and Taste Dysfunction After SARS-CoV-2 Infection. 
Demonstrates the wide range of anosmia prevalence between studies. Taken from and for references within the 








It is important to have a reliable and accurate assessment method in order to 
diagnose olfactory dysfunction. Anosmia is one of the earlier symptoms of the COVID-
19 disease, and efficient detection of this symptom can have significant epidemiological 
impact. Hannum et al. found that objective methods reported a higher prevalence of 
olfactory loss when compared to subjective methods, underestimating the perceived onset 
of anosmia among COVID-19 patients (Hannum et al., 2020). Diagnosis methods include 
subjective assessment, psychophysical olfactory assessment, and imaging (Whitcroft & 
Hummel, 2019). 
Treatment options of anosmia include corticosteroids, vitamin A, and olfactory 
training (Whitcroft & Hummel, 2019; Izquierdo-Dominguez et al., 2020). Studies show 
that corticosteroids are effective for treating olfactory loss in patients with chronic 
inflammatory sinonasal disease due to chronic rhinosinusitis (CRS) (Fong, Kern, Foster, 
Zhao, & Pitovski, 1999). Patients experiencing hypoanosmia have elevated levels of 
proinflammatory cytokines, and corticosteroids may have anti-inflammatory effects and 
modulate the NA, K-ATPase enzyme to increase olfactory mucus secretion (Fong et al., 
1999; Yan, Overdevest, & Patel, 2019). In addition, the method of delivery seems to be 
important as well. Yan et al. 2019 reviewed studies that specifically looked at steroid use 
on olfactory loss and found that topical steroid spray were not an effective treatment 
option, while topical steroid irrigation improved olfactory function among patients (Yan 
et al., 2019). 
It is widely accepted that for healthy people without olfactory dysfunction, 
olfactory training by repeated exposure to an odorant can decrease the threshold at which 
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the odor is detected (Izquierdo-Dominguez et al., 2020). Many clinical studies have 
shown this therapy may is effective for patients with hyposmia or anosmia (Patel, 2017; 
Sorokowska, Drechsler, Karwowski, & Hummel, 2017; Hummel et al., 2009). 
Vitamin A is a promising treatment for people suffering from loss of smell 
because vitamin A is important for regenerating olfactory receptor neurons, which are 
vital for the functionality of olfactory transduction to occur (Izquierdo-Dominguez et al., 
2020).  Hummel et al. grouped 170 patients with post-infectious and posttraumatic smell 
disorders into either the smell training only or the smell training and topical vitamin A 
group (Hummel et al., 2017). The results showed that when patients received a dose of 
10,000 IU/day of vitamin A for 8 weeks and received olfactory training, 37% of post-
infectious patients showed improvement, whereas only 23% showed improvement in the 
olfactory training only group. There was no significant difference between the two 
groups for the patients with olfactory loss due to trauma (Hummel et al., 2017). However, 
the patient population we are interested in are COVID-19 patients with olfactory loss 
with viral etiology. The results from this study show promise for treating post-infectious 
olfactory dysfunction.   
The above treatments are noninvasive, but the side effects of the drugs and 
limitations of studies should be considered as well. Olfactory mucus is an essential 
substance that coats the apical receptor surface of the neuroepithelium; this substance, 
secreted by the acinar cells of Bowman’s gland, is critical for olfactory transduction 
(Fong et al., 1999). There is a possibility that corticosteroids affect olfactory secretion 
since corticosteroids have a role in modulating the sodium-potassium-adenosine 
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triphosphate (Na, K-ATPase) enzyme in salivary glands and the olfactory mucosa have 
corticosteroid receptors (Fong et al., 1999). The studies are limited in that they may not 
have controlled for confounding variables such as patient age and etiology of the loss of 
smell. With the limitations identified, the data from these studies are still useful for the 
purpose of treating anosmia with viral etiologies.  
According to Berlit et al., the prognosis of anosmia and ageusia associated with 
COVID-19 is favorable as most patients recover within 2-3 weeks of symptom onset 
(Berlit et al., 2020). However, the same researchers estimate 10-20% of patients continue 
to have limitations to some extent (Berlit et al., 2020).  
 
Multi-system Inflammatory Syndrome in Children (MIS-C) and Adults (MIS-A) 
There is emerging evidence of a rare illness that is affecting children who  
have had COVID-19: Multi-system inflammatory syndrome. Increasing reports of this 
illness prompted the Centers for Disease Control and Prevention (CDC) to give an 
official health advisory in May 2020 (Centers for Disease Control and Prevention [CDC], 
2020). To help healthcare providers recognize this vague syndrome, CDC provided a case 
definition for MIS-C: The individual must be less than 21 years of age, suspected or 
confirmed to have COVID-19, present with fever and inflammation, and have 
multisystem involvement (CDC, 2020). Any individual who meets these criteria, and 





Rash, neurological symptoms, gastrointestinal symptoms and severe inflammation 
affecting the cardiovascular system seem to be the common among MIS-C patients (Tang 
et al., 2021). The study by Mahmoud et al. support these findings (Mahmoud et al., 
2021). In their study of 64 MIS-C patients, 55 (86%) had cardiac manifestations and 50 
(78%) had gastrointestinal involvement (Mahmoud et al., 2021). The Dufort et al. study 
supports this finding since 36% of the case patients in the study were suspected to have 
Kawasaki’s disease (KD) or atypical Kawasaki’s disease (KD) and 36% had myocarditis 
(Dufort et al., 2020). The symptoms presented in MIS-C and Kawasaki disease (KD) 
overlap (Tang et al., 2021). KD usually presents itself as rash, conjunctivitis, 
lymphadenopathy, and peeling skin on hands and feet (McMurray, May, Cunningham, & 
Jones, 2020; Tang et al., 2021). The study by Dufort et al. found that neurological 
manifestations were experienced by 38% of patients aged 13 to 20 years; a significantly 
lower number, 13% were experienced in patients aged 0 to 5 years (Dufort et al., 2020). 
Since respiratory symptoms are not common in MIS-C patients, it may be possible to 
overlook this syndrome to be associated with COVID-19. It is especially true when this 
disease peaks weeks after SARS-CoV-2 infection and manifests itself as similar diseases 
such as Kawasaki’s disease. The study by Dufort et al. (Figure 7)  shows the prevalence 
of myocarditis in MIS-C cases indicate that the cardiovascular system is one of the most 





Figure 7. Percent of Multisystem Inflammatory Syndrome in Children (MIS-C) Patients Presenting with 
Symptoms According to Age Group. Taken from (Dufort et al., 2020).  
 
However, the study also shows that the percent of patients with myocarditis 13 to 20 
years of age is higher than in younger patients. This pattern could be significant for 
recognizing this syndrome in adults patients. In addition, the Dufort et al. study shows 
that the percent of patients with either a Kawasaki disease (KD) or atypical Kawasaki 
disease (KD) diagnosis is higher in patients aged 0 to 12 years when compared to 13 to 
20 years (Figure 7). The clinical symptoms of KD present as rashes and other easily 
observable symptoms, which make it more easily recognized. The disparity in organ 
systems involved according to age group could explain the higher prevalence of MIS-C 
cases compared to MIS-A cases.  
The multisystem involvement of MIS-C makes it difficult to figure out the 
specific pathogenesis of this syndrome. However it is clear that the IL-1β pathway is 
involved in the pathogenesis of MIS-C (McMurray et al., 2020). After a viral infection, 
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the nod-like receptor family pyrin domain-containing protein 3 (NLRP3) becomes 
activated (McMurray et al., 2020). NLRP3 is part of an inflammasome complex that in 
turn activates caspase-1 to cleave cytokines of the innate immune system (McMurray et 
al., 2020). The increase in matured IL-1β is followed by a pro-inflammatory environment 
including IL-6, IL-8 and TNF-a (McMurray et al., 2020). Lymphopenia, or decreased 
levels of lymphocytes in the blood, are associated with increased IL-6 levels. (McMurray 
et al., 2020). The pathogenesis of MIS-A needs to be investigated in future studies. The 
pathogenesis of MIS-A may be very similar to that of MIS-C. In addition, the pediatric 
cases of MIS may be more evident because of the sudden onset of symptoms in patients 
with a healthy medical history (Tenforde & Morris, 2021). On the other hand, children 
are less tested, and it is estimated that up to 45% of pediatric COVID-19 cases are 
asymptomatic (Dufort et al., 2020; McMurray et al., 2020).  
In addition to MIS-C, there have been emerging reports of MIS-A. 
MIS-A seems to be less prevalent, so at this time there is no official case definition 
released (Tenforde & Morris, 2021). The working case definition is similar to the case 
definition for MIS-C. The differences are that the patient must be 21 or older and present 
with severe dysfunction in at least one extrapulmonary system (Morris et al., 2020). 
Morris et al. identified 16 patient cases that were reported to the CDC and obtained from 
published reports that met this working case definition (Morris et al., 2020). An 
interesting finding was that 12 of the 16 patients present with a fever and all patients had 
some form of cardiac dysfunction (Morris et al., 2020). A study by Hékimian et al. 
supports this finding: The researchers found that 8 of 11 patients ages 16 and older who 
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presented with myocarditis had MIS (Hékimian et al., 2021). A majority of the patients 
had cardiac symptoms such as hypotension and tachycardia; about half the patients 
showed signs of acute coronary syndrome. All the patients in the study had clinical and 
laboratory evidence of myocarditis. Only 2 of the patients had symptomatic COVID-19 
one month prior, demonstrating that SARS-CoV-2 serology testing is crucial for the 
identification of MIS.  
A case study by Ahsan & Rani describes a 28-year-old male patient who fulfilled 
the working definition of MIS-A (Ahsan & Rani, 2020). His clinical presentations 
included severe aching in the legs, swelled feet, confusion, behavioral change, and 
muscle weakness. One of the most targeted systems was the nervous system, in this case, 
demonstrating the neurological involvement in MIS-A (Ahsan & Rani, 2020). 
The studies on MIS-A may not be underreporting the number of cases; the 
working definition excludes respiratory dysfunction and it is possible that someone with a 
severe clinical presentation of COVID-19 has MIS-A (Morris et al., 2020). The accuracy 
in diagnosing MIS is important because it is unclear if the specific treatments for patients 
with Kawasaki disease is effective for treating MIS (Hékimian et al., 2021).  
 
Diagnosis and Treatment of MIS-C and MIS-A 
 
The diagnosis of MIS-C and MIS-A is made by laboratory tests and clinical presentation 
that fulfill the case definition of MIS-C and MIS-A. The severity of MIS-C requires 
many patients to be admitted to pediatric intensive care unit. Tang and colleagues 
investigated recent case studies on patients with MIS-C (Tang et al., 2021). They found 
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that more patients tested positive for SARS-CoV-2 by serology compared to RT-PCR, 
supporting the observation that many patients present with MIS-C 4-5 weeks after 
recovering from COVID-19 (Belot et al., 2020). They also showed that laboratory 
findings revealed a pattern among patients: Elevated inflammatory indicators such as C-
reactive protein (CRP), procalcitonin, and ferritin (Tang et al., 2021). Treatment of MIS-
A include intravenous immunoglobulin and steroids (Tenforde & Morris, 2021). In Tang 
et al., the treatments used for the majority of MIS-C patients was autoimmune treatment, 
anticoagulants, and steroids.  
Certain ethnic groups appear to be more vulnerable to MIS-C. A large proportion 
of MIS-C patients are Hispanic/Latino and non-Hispanic Black populations. There could 
be a genetic factor that increases the susceptibility of these patients (CDC, 2020; Tang et 
al., 2021). However, this finding correlates to the data that shows populations that are 
burdened by COVID-19 the most are Hispanic/Latino and non-Hispanic Black 
populations (CDC, 2020). It is also possible that both genetic and environmental factors 
contribute to the vulnerability to MIS-C. Both factors, genetic and environmental, need to 
be evaluated to assess whether an individual is susceptible to MIS-C. It is important to 
keep MIS-C as a differential diagnosis when there are children present with Kawasaki’s 
disease symptoms because although they present in similar ways, they may require 
different treatments. Also, since MIS-C is mostly diagnosed with SARS-CoV-2 serology 
tests, there is a high possibility the number of MIS-C cases are underreported (Dufort et 




Long-Term Neurological Sequelae of COVID-19  
 
Next, the long-term neurological sequelae of COVID-19 will be discussed. There is 
ongoing evidence that COVID-19 is connected to many neurological conditions, acute 
and long-term. The long-term sequelae of COVID-19 seem to be the reflection of the 
hyperinflammatory environment created by the acute phase of the infection. Discussed 
above were acute neurological conditions that present shortly after SAR-CoV-2 infection. 
However, the long-term sequelae of COVID-19 present more slowly and therefore must 




Depression is one of many psychiatric disorders that are associated with COVID-19. It is 
important to investigate depression because this disorder is highly prevalent, but also 
highly treatable (Cuijpers, Quero, Dowrick, & Arroll, 2019). The urgency to investigate 
is increased during the COVID-19 pandemic since there may be a connection between 
SARS-CoV-2 and depression. A study found that out of 144 confirmed COVID-19 
patients, about 28% had depression, based on questionnaires the patients took (Kong et 
al., 2020). The researchers also found that there is a correlation between less social 
support and depression (Kong et al., 2020). During the COVID-19 pandemic, public 
health officials encourage physical distancing and other measures that may increase the 
perception of less social support. Thus, depression is a complex neurological disorder 
with both a biological and social etiology that needs to be reviewed. Since COVID-19 
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patients have to be isolated during their treatment, they may have an increased sense 
loneliness. There have been reports where medical staff in Wuhan hospitals would 
interact with patients by practicing Tai Chi and engaging in other recreational activities. 
This positive interaction with hospital staff could decrease the occurrence of developing 
mental illnesses (Kong et al., 2020). Just as some of the other neurological manifestations 
are linked to severity of the patient’s COVID-19 disease, disease severity is more likely 
to cause anxiety in patients (Kong et al., 2020). Patients with severe COVID-19 illness 
should receive more mental health assessments to see if they need psychological 
intervention (Kong et al., 2020).  
The biological cause of depression is presumed to be the decreased levels of 
monoaminergic neurotransmitters such as serotonin (Park & Zarate, 2019). The cytokine 
storm could be implicated with the onset of depression in COVID-19 patients. 
Proinflammatory cytokines exacerbate psychiatric disorders such as depression by the 
enzyme indoleamine 2,3 dioxygenase (IDO) (Wichers et al., 2005). Induced by the 
proinflammatory cytokine IFN-y, IDO degrades tryptophan (TRP) into kynurenine 
(KYN) and therefore decreases the levels of serotonin (Wichers et al., 2005; Orsini et al., 
2020). Decreased levels of serotonin may be involved in psychiatric conditions including 
depression (Cowen and Browning, 2015).  
A study compared the immunoglobulin G levels between patients who recently 
experienced a psychotic event and nonpsychotic controls. They found that the antibody 
levels against the four human coronavirus strains (229E, HKU1, NL63, and OC43) were 
higher in patients who recently presented with a psychotic event compared to the 
 
40 
nonpsychotic control group (Severence et al., 2011). The findings indicate there may be 
an association between coronavirus infection and psychotic symptoms. In addition, one 
human coronavirus strain (HCoV-NL63) being detected in a patient’s serum is correlated 
with a history of mood disorder (Troyer, Kohn, & Hong, 2020).  
In addition to the pathophysiological effects of SARS-CoV-2, it is imperative to 
understand the psychological and social effects of the COVID-19 pandemic (Holmes et 
al., 2020). Vulnerable populations during a pandemic include people with diagnosed 
mental health issues, physical disability, loss of employment and other factors that lead to 
social inequality (Holmes et al., 2020). The anxiety of contracting the highly infectious 
disease is also a factor that could be lead to psychological distress, contributing to an 
impaired quality of life (Kong et al., 2020). The COVID-19 pandemic protocols such as 
physical distancing and quarantines have inadvertently caused increased social isolation 
and loneliness. A decreased social network is linked with psychological issues such as 
anxiety, depression, self-harm, and suicide (Holmes et al., 2020). The SARS-CoV 
epidemic in 2003 demonstrates the aftereffects of a widespread public health outbreak: 
The epidemic had major psychological consequences for both the SARS-CoV patients 
and their families (Tsang et al., 2004). Previous experiences can provide insight on how 
to more efficiently support vulnerable populations. 
 
Diagnosis and Treatment of Depression 
 
Questionnaires can be used in the primary care and outpatient settings to screen for 
depression (Park & Zarate, 2019). Due to the wide range of presentations of depression, 
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the Diagnostic and Statistical Manual of Mental Disorders, fifth edition is used by 
healthcare providers to ensure a consistent and comprehensive assessment (Park & 
Zarate, 2019). Kong et al. created a psychological-behavioral intervention program, a 
type of  psychological intervention combined with breathing exercises; the psychological 
intervention consisted of teaching self-management skills to patients, encouraging 
emotional expression and confidence (Kong et al., 2020). The researcher found that PBI 
was successful in reducing anxiety and depressing among the participants when 
compared to controls (Kong et al., 2020). Psychotherapy can take many forms and is 
usually recommended for patients with mild or moderate level of depression. One of the 
more well-known types of psychotherapy is cognitive-behavior therapy (CBT). CBT 
helps patients to change their behavior by challenging negative emotions and thoughts 
(Cuijpers et al., 2019). Virtual psychotherapy is also an effective alternative to in-person 
therapy. This is beneficial for patients during the COVID-19 pandemic (Park & Zarate, 
2019). Pharmacotherapy is also used for the treatment of depression. Selective serotonin-
reuptake inhibitors (SSRIs) are a common prescription. SSRIs work by increasing 
serotonin levels. Although both psychotherapy and antidepressant medications are 
beneficial in managing depression in the short-term, there is evidence that psychotherapy 
is more effective in the long-term (Cuijpers et al., 2019).  
The psychological stress the COVID-19 pandemic has cannot be overlooked.  
SARS-CoV medications like ribavirin and corticosteroids could be implicated with some 
psychological effects of infected people. They cause side effects that include cosmetic 
changes such as hair loss, memory loss, impaired concentration, and depression (Tsang et 
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al., 2004). Thus, these drugs could be confounding variables that lead to overestimates of 
the number of patients who experience psychological symptoms directly from SARS-
CoV.  
 
Alzheimer’s Disease  
 
There is ongoing evidence that COVID-19 is connected to many neurological conditions. 
However, the long-term sequelae of COVID-19 may take several years to present, 
currently making it difficult to make any conclusive connections. Alzheimer’s is a 
neurodegenerative disease that affects an estimated 10-30% of the geriatric population 
(Ding, Shults, Gychka, Harris, & Suzuki, 2021). Ding et al., found that ACE2 
upregulation is implicated with oxidative stress in the brain, and therefore these two 
factors are associated with Alzheimer’s disease (Ding et al., 2021). Since ACE2 is the 
receptor for SARS-CoV-2, patients with Alzheimer’s are more susceptible to infection 
(Ding et al., 2021). The disease causes severe cognitive and physical impairments that are 
due to neuronal loss from amyloid-β plaques and neurofibrillary tangles (Sochocka, 
Zwolińska, & Leszek, 2017). The amyloid-β plaques are made of beta-amyloid (Aβ) 
peptides that cleaved from the transmembrane protein, amyloid precursor protein (APP) 
(Abate et al., 2020). When there is a viral infection, the innate immune response is 
triggered and cytokines and other mediators are released. (Sochoka et al., 2017). 
Microglia and astrocytes, innate immune cells in the brain, respond to cytokines and 
through a cascade of events, even more pro-inflammatory cytokines are produced 
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(Heneka et al., 2015). ACE2 expression in glial cells indicate the potential infection of 
SARS-CoV-2 (Kanwar et al., 2020). Thus, SARS-CoV-2 infection could infect microglia, 
causing chronic neuroinflammation and neuronal damage due to their connection with 
pro-inflammatory cytokines and reactive oxygen species (Abate et al. 2020). In addition, 
Soscia et al. found that amyloid-β proteins may be a part of the innate immune system by 
acting as an antimicrobial peptide (AMP) (Soscia et al., 2010). Thus, SARS-CoV-2 
infection can lead to continuous amyloid-β plaque production due to their antimicrobial 
activity the chronic inflammatory response in the brain (Heneka et al., 2015; Abate et al., 
2020; Soscia et al., 2010). Although acute neuroinflammation promotes repair in the 
brain, chronic neuroinflammation has the opposite effect. Thus, the association between 
SARS-CoV-2 may need to be considered for the long-term (Sochoka et al., 2017).  
Alzheimer’s disease progresses extremely slow and takes 10-20 years before the 
patient presents with any symptoms (Abate et al., 2020). A study found that brains from 
patients with Alzheimer’s disease are more susceptible to SARS-CoV-2 infection due to 
their higher brain ACE2 expression (Ding et al., 2021). They also found that this 
relationship was not graded. That is, that ACE2 was upregulated in all Alzheimer’s 
disease patients regardless of disease severity.  
 
Diagnosis and Treatment of Alzheimer’s Disease 
 
Patients can be diagnosed with Alzheimer’s disease by the clinical presentation of the 
patient, biomarkers, and imaging. Aβ42 and hyperphosphorylated tau peptide (p-tau) are 
biomarkers for Alzheimer’s disease that can be obtained from the cerebral spinal fluid 
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(CSF). A less invasive method is imaging by a positron emission tomography scan of the 
brain to reveal amyloid-β plaques (Weller & Budson, 2018). During the pandemic, 
patients are more likely to receive healthcare though telemedicine. The lack of extensive 
work up and equipment required to diagnose neurocognitive disorders risk 
underdiagnoses of Alzheimer’s disease (Brown, Kumar, Rajji, Pollock, & Mulsant, 
2020).  
Currently, there is no cure for Alzheimer’s disease. However, there are some 
ways to manage the disease. Common pharmacologic management are cholinesterase 
inhibitors and memantine, a dopamine agonist (Brown et al. 2020). Other pharmacologic 
treatments against Alzheimer’s include non-steroidal anti-inflammatory drugs (NSAIDs) 
since inflammation is implicated in the pathogenesis of the disease (Sochoka et al., 2017).  
Nonpharmacologic management include social contact, exercise, and pet therapy (Brown 
et al., 2020).  
 
Patients with Alzheimer’s disease could be less likely to comply with public health 
recommendations of physical distancing and practicing hand hygiene depending on the 
severity of their disease (Fotuhi et al., 2020). The diagnosis and management of patients 
with Alzheimer’s disease are negatively impacted by the current pandemic. Social 
isolation due to the pandemic most likely exacerbates and increases the prevalence of the 
disease. For example, in a cohort study by Wilson et al., they found that perceived 
loneliness such as from social isolation had a positive correlation with dementia (Wilson 
et al., 2007).  
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Neurological conditions are complex and interconnected. For example. Anosmia 
is associated with some variations of Alzheimer’s disease (Olichney et al., 2005).  
Long-term neurological sequelae such as depression and Alzheimer’s disease would be 





Throughout this thesis, the acute and long-term sequelae of neurological manifestations 
associated with COVID-19 were reviewed. The published studies discussed acute 
neurological characteristics involving Guillain-Barré syndrome, strokes, seizures, MIS-C, 
and MIS-A. The long-term diseases discussed were depression and Alzheimer’s disease. 
The studies involving the acute conditions, and diseases, and diseases provide some 
evidence that COVID-19 could be associated to them. However, due to the rare 
occurrences, widespread clinical presentations, and long duration of pathogenesis of 
Guillain-Barré syndrome, MIS-C, MIS-A, depression, and Alzheimer’s disease, more 
research is needed to support the current findings. Other limitations in several studies in 
this thesis are due to a low number of participants and narrow geographic area. For 
instance, the study by Li Yanan et al. only involved 219 patients from Wuhan, Hubei 
Province. In the research study conducted by Mao et al., only 214 patients from Wuhan, 
China were included. SARS-CoV-2 originated in Wuhan, China, so it is reasonable that 
the first major published studies occurred in that geographical area. Nonetheless, these 
studies provide insight into the potential of SARS-CoV-2 infection to cause neurological 
concerns. As more studies are being released about patients from different countries, the 
findings from the studies in Wuhan, China can be compared.  
The knowledge that SARS-CoV-2 can have neurologic implications support 
paradigm that other extrapulmonary systems may also be affected. There is much work to 
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be done on neurological conditions associated with COVID-19 due to the constant, 
ongoing discoveries in this topic.  
The possibility of SARS-CoV-2 variants forming is high due to the coronavirus 
genome being prone to mutations during viral replication (Koyama, Weeraratne, 
Snowdon, & Parida 2020). The current COVID-19 vaccines may or may not be effective 
since host antibodies may no longer recognize these new variant strains. It is important 
for biotechnology companies and researchers to consider the possibility of variants 
forming when designing vaccines. However, the future is hopeful in that approved 
COVID-19 vaccines are currently being dispersed worldwide. A phase III clinical trial 
with 30,000 participants aged 18-95 found that Moderna’s COVID-19 vaccine was 
94.1% effective in preventing COVID-19 illness (Oliver et al., 2021). However, the 
94.1% efficacy against COVID-19 was only after two doses that are approximately 4 
weeks apart were received (Oliver et al., 2021). The need for two doses, the period to 
gain effective immunity, and the limited amount of vaccines available are reasons to 
believe the COVID-19 pandemic will continue for some time. Ongoing COVID-19 cases 
may continue to cause acute and long-term neurological diseases and other medical 
conditions. It is critical to continue research in this subject because the numerous 
published studies reviewed in this thesis indicate the possibilities of neurological 
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